Tag

Lilly

All articles tagged with #lilly

business6 hours ago•2 min saved

Lilly expands infectious-disease portfolio with three-broker vaccine acquisitions

Eli Lilly is buying Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8 billion in upfront and milestone payments to broaden its infectious-disease pipeline. Curevo brings a shingles vaccine candidate, LimmaTech adds a Staphylococcus aureus vaccine program, and Vaccine Company offers vaccines targeting flaviviruses and an EBV-focused program, signaling Lilly’s shift toward preventative vaccines and a strategy to build a diversified vaccine portfolio alongside its strong oncology and metabolic franchises.

via Fierce Biotech|

#acquisitions #business #curevo

business1 day ago•6 min saved

Lilly bets on prevention with three biotech acquisitions

Lilly announced agreements to acquire Curevo, LimmaTech Biologics and Vaccine Company to broaden its infectious-disease portfolio with vaccine-based prevention for shingles, bacterial pathogens and EBV-related disease, respectively. The deals could total up to $3.83 billion in potential cash payments, contingent on milestones and regulatory clearances, and closing is subject to customary conditions, reflecting Lilly's strategy to prevent disease at the source and address antimicrobial resistance.

via PR Newswire|

#antimicrobial-resistance #business #infectious-disease

business1 day ago•6 min saved

Lilly bets on prevention with triple acquisitions to boost infectious-disease portfolio

Lilly will acquire Curevo, LimmaTech Biologics, and Vaccine Company to broaden its infectious-disease portfolio, spanning a shingles vaccine candidate, a bacterial-pathogen vaccine platform, and an EBV-focused virus-like particle vaccine, for up to about $3.83 billion in cash and milestone payments, subject to closing conditions.

via investor.lilly.com|

#acquisitions #biopharma #business

business5 days ago•3 min saved

Lilly’s triple-hormone obesity drug posts strong Phase 3 weight loss, but data gaps temper optimism

Lilly’s triple-G obesity drug retatrutide met primary endpoints in Phase 3 TRIUMPH-1, delivering up to 28.3% weight loss at 80 weeks for the highest dose on the efficacy estimand (vs 2.2% for placebo). On the treatment-regimen estimand, weight losses were 17.6% (4 mg), 23.7% (9 mg) and 25% (12 mg) with placebo at 3.9%. A Week 104 readout for the top dose reached 29.9% among patients who stayed on therapy. The topline did not include sleep apnea or osteoarthritis pain data. Safety showed higher discontinuations at the high dose (11.3% vs 4.9% placebo) and notable dysesthesia (20.9% at high dose); GI adverse events were more common at the low dose. Analysts said the results meet key endpoints but didn’t exceed expectations, and Lilly is eyeing possible FDA submission this year amid competition from Wegovy and other obesity drugs.

via Fierce Biotech|

#business #lilly #obesity

health6 days ago•23 min saved

Lilly’s retatrutide drives sustained, substantial weight loss in Phase 3 obesity trial

In the TRIUMPH-1 Phase 3 trial, Lilly’s triple hormone agonist retatrutide produced clinically meaningful weight loss across all dose groups over 80 weeks: 12 mg yielded an average 70.3 lb loss (28.3%) with 45.3% achieving ≥30% weight reduction, and 65.3% reached BMI 22 at Week 80; 9 mg achieved 64.4 lb (25.9%) and 4 mg 47.2 lb (19.0%). An extension up to 104 weeks showed continued weight loss in some participants, including those with higher baseline BMI. The data support retatrutide’s potential as a non-surgical obesity treatment, with detailed safety labeling included in the release.

via investor.lilly.com|

#health #lilly #obesity

business21 days ago•24 min saved

Lilly ramps up Indiana manufacturing with $4.5B push, opens first dedicated genetic medicine facility

Eli Lilly announced a further $4.5 billion in Indiana manufacturing investments across two Lebanon, Ind., sites — Lebanon API and its first dedicated genetic medicine facility, Lebanon Advanced Therapies — bringing total Indiana commitments since 2020 to over $21 billion. The Lebanon campus will include API, Advanced Therapies, and a Foundry, with the site expansion supporting current and future medicines (including Zepbound and Mounjaro) and products like Foundayo and retatrutide. The company says Lebanon API is slated to become the largest U.S. API production site when it opens in 2027, underscoring Lilly’s broader domestic manufacturing expansion and economic impact.

via investor.lilly.com|

#business #genetic-medicine #indiana

business27 days ago•18 min saved

Lilly lifts 2026 outlook after strong Q1 2026 results and Foundayo FDA approval

Lilly posted a 56% YoY surge in Q1 2026 revenue to $19.8B, with GAAP EPS of $8.26 and non-GAAP EPS of $8.55, driven by volume growth despite lower realized prices; raised full-year revenue guidance to $82–$85B and non-GAAP EPS to $35.50–$37.00; highlighted regulatory progress including FDA approval of Foundayo (orforglipron) for obesity, plus pipeline advances across multiple programs; announced four acquisitions (Orna Therapeutics, Centessa, Kelonia, Ajax Therapeutics); and plans an Investment Community Meeting for December 7, 2026.

via investor.lilly.com|

#acquisitions #business #foundayo-approval

business27 days ago•3 min saved

Lilly lifts 2026 outlook on booming GLP-1 drugs

Eli Lilly beat Q1 estimates with about $19.8B in revenue and $8.55 in adjusted EPS, powered by 125% growth in Mounjaro to $8.66B worldwide and $4.2B in U.S. sales, and $4.16B in U.S. Zepbound sales. The results prompted a $2B raise to full-year revenue guidance to $82–85B and higher adjusted EPS of $35.50–$37. Foundayo, the obesity GLP-1 pill, launched in Q2 and isn’t included in this report. Lilly maintains roughly 60% of the U.S. GLP-1 market, but faces pricing pressure and upcoming Medicare coverage changes as global GLP-1 use could reach about 30M by end-2026.

via CNBC|

#business #foundayo #glp-1

business29 days ago•2 min saved

Lilly to Acquire Ajax for $2.3B to Push Next-Gen JAK2 Inhibitor AJ1-11095

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in phase 1 for myelofibrosis. Lilly says the Type II inhibitor could yield deeper and more durable efficacy than existing Type I JAK2 inhibitors and help patients who develop resistance, based on Ajax’s preclinical data and a Schrödinger collaboration. The deal comprises upfront and milestone payments, and Lilly plans registrational trials after forthcoming proof-of-concept data in 2026, underscoring its ongoing aggressive biotech dealmaking.

via Fierce Biotech|

#aj1-11095 #ajax-therapeutics #business

business1 month ago•5 min saved

Lilly to acquire Ajax Therapeutics to advance next-gen JAK2 therapy for myeloproliferative neoplasms

Lilly has a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion in cash to accelerate AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for myeloproliferative neoplasms (myelofibrosis and polycythemia vera). AJ1-11095 is designed to bind a different JAK2 conformation for deeper, more durable efficacy and tolerability, with clinical proof-of-concept data expected later in 2026 and plans to move into registrational trials across first- and second-line settings.

via investor.lilly.com|

#aj1-11095 #ajax-therapeutics #business

business1 month ago•6 min saved

Lilly to acquire Ajax Therapeutics to push next-gen JAK2 inhibitor for MPNs

Eli Lilly will acquire Ajax Therapeutics in a deal worth up to $2.3 billion to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. Designed for deeper, more durable efficacy than current JAK2 inhibitors, AJ1-11095 aims to enable longer therapy duration and broader use across first- and second-line settings, with proof-of-concept data anticipated later in 2026 and registrational trials planned.

via PR Newswire|

#ajax-therapeutics #business #jak2

business1 month ago•5 min saved

Lilly Expands In Vivo CAR-T Strategy with Kelonia Acquisition

Eli Lilly to acquire Kelonia Therapeutics in a deal potentially worth up to $7 billion to advance KLN-1010, an in vivo CAR-T therapy for multiple myeloma using the iGPS delivery platform, with the aim of bypassing ex vivo manufacturing and expanding access; closing is expected in the second half of 2026 after customary regulatory approvals.

via investor.lilly.com|

#business #igps #in-vivo-car-t

business1 month ago•3 min saved

Lilly bets on dual-payload ADCs with CrossBridge Bio acquisition

Eli Lilly is acquiring CrossBridge Bio in a deal potentially worth $300 million to broaden its portfolio of antibody-drug conjugates, notably dual-payload ADCs like CBB-120 targeting TROP2; the structure of upfront versus milestone payments wasn’t disclosed, and CrossBridge aims to advance its lead candidate into the clinic this year.

via Fierce Biotech|

#antibody-drug-conjugates #biotech #business

business1 month ago•12 min saved

Lilly to acquire Centessa to accelerate orexin-based sleep-wake therapies

Eli Lilly will acquire Centessa Pharmaceuticals for up to $47 per Centessa share (cash of $38 plus a non-transferable contingent value right) in a deal valued at about $6.3 billion upfront with up to $1.5 billion more via CVR milestones, expanding Lilly’s neuroscience portfolio into sleep medicine. Centessa’s lead orexin receptor 2 (OX2R) agonist program, led by cleminorexton (formerly ORX750), targets narcolepsy types 1 and 2 and idiopathic hypersomnia and is supported by additional assets across neurological indications. The transaction is subject to Centessa shareholder and regulatory approvals and is expected to close in Q3 2026.

via Eli Lilly|

#business #centessa #lilly

business3 months ago•5 min saved

Lilly’s Orforglipron Edges Novo’s GLP-1 Pill in Major Diabetes Trial

In a year-long, head-to-head trial with 1,698 diabetes patients, Eli Lilly’s oral GLP-1 pill orforglipron outperformed Novo Nordisk’s Rybelsus on blood sugar control and weight loss (roughly 15–20 lbs vs 8–11 lbs), with better cardiovascular markers. Higher doses brought more GI side effects (about 10% dropout). The pill can be taken anytime, doesn’t require refrigeration, and Lilly aims for U.S. availability by mid-2026 at about $145–$399 out of pocket.

via Business Insider|

#business #diabetes #glp-1